Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 12

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 12
---
                                                                           |

| 8 |

<div align='center'>RISK FACTORS</div>

Our business has significant risks. You should consider carefully the risks set forth below and other information in this prospectus, including the information contained under the heading “Risk Factors” in our 2023 Annual Report and incorporated herein by reference, before you decide to purchase our securities. These risks and uncertainties are not the only risks and uncertainties we may face. Additional risks and uncertainties not presently known to us, or that we currently consider immaterial could also negatively affect our business, financial condition, results of operations, prospects, profits and share prices. If any of the risks described below actually occur, our business, financial condition, results of operations, prospects, profits and share prices could be materially adversely affected. See also the information contained under the heading “Cautionary Statement Regarding Forward-Looking Statements” herein.

The sale of a substantial amount of our Ordinary Shares (represented by Depositary Shares), including resale of the Ordinary Shares (represented by Depositary Shares) issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our Ordinary Shares and/or Depositary Shares.

We are registering for
resale 171,700,000 Ordinary Shares represented by 1,717 Depositary Shares issuable upon the exercise of warrants held by the selling
shareholders. Sales of substantial amounts of our Ordinary Shares and/or Depositary Shares in the public market, or the perception that
such sales may occur, could adversely affect the market price of our Ordinary Shares and/or Depositary Shares. We cannot predict if and
when selling shareholders may sell such shares in the public markets. Furthermore, in the future, we may issue additional Ordinary Shares
(including Ordinary Shares represented by Depositary Shares). Any such issuance could result in substantial dilution to our existing
shareholders and could cause our share price to decline.

| 9 |

<div align='center'>USE OF PROCEEDS</div>

We will not receive any
proceeds from the sale of the Ordinary Shares represented by Depositary Shares issuable upon the exercise of the December 2023 Private
Placement Pre-Funded Warrants by the selling shareholders. All net proceeds from the sale of the Ordinary Shares underlying the December
2023 Private Placement Pre-Funded Warrants covered by this prospectus will go to the selling shareholders. However, upon any exercise
of the December 2023 Private Placement Pre-Funded Warrants for cash, the